title: Clinical status of carboplatin.
abstract: Carboplatin, a cisplatin derivative, shows promise of being an effective weapon against ovarian, cervical, and small-cell lung cancer, as well as epidermoid cancer of the head and neck, with fewer toxic effects than cisplatin. It has successfully completed phase III investigation and clinical trials continue.
authors.affiliation: Bristol-Myers Company, Pharmaceutical Research and Development Division, Wallingford, Connecticut.
authors.forename: R
authors.initials: R
authors.lastname: Canetta
authors.forename: C
authors.initials: C
authors.lastname: Franks
authors.forename: L
authors.initials: L
authors.lastname: Smaldone
authors.forename: K
authors.initials: K
authors.lastname: Bragman
authors.forename: M
authors.initials: M
authors.lastname: Rozencweig
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents; D016190:Carboplatin; D002460:Cell Line; D002945:Cisplatin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D016190:Carboplatin; D002945:Cisplatin